https://www.selleckchem.com/pr....oducts/hpk1-in-2.htm
Moreover, hsa-miR-128a targeted BMI-1 and might played a role in the p53 pathway. Hsa-miR-128a boosted the effect of pembrolizumab on laryngeal cancer cells, perhaps via the p53 pathway. Therefore, hsa-miR-128a might be a novel target in laryngeal cancer treatment. Hsa-miR-128a boosted the effect of pembrolizumab on laryngeal cancer cells, perhaps via the p53 pathway. Therefore, hsa-miR-128a might be a novel target in laryngeal cancer treatment. Nonsmall cell lung cancer (NSCLC) is the most common type of lung cancer, and the majority
Like
Comment
Share
